Davis Robert E 4
4 · Intra-Cellular Therapies, Inc. · Filed Dec 6, 2017
Insider Transaction Report
Form 4
Davis Robert E
SVP, Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2017-12-04+1,757→ 28,514 total - Sale
Common Stock
2017-12-05$15.00/sh−650$9,750→ 27,864 total - Exercise/Conversion
Restricted Stock Units
2017-12-04−1,757→ 1,758 total→ Common Stock (1,757 underlying)
Footnotes (5)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. The proceeds from this sale will be used primarily to cover the reporting person's tax liability arising from the vesting of restricted stock units.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]Each restricted stock unit represents a contingent right to receive one share of common stock.
- [F5]On December 4, 2015, the reporting person was granted 5,272 restricted stock units, vesting in three equal instalments beginning on the first anniversary of the grant date.